WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Dr. R. Anil Kumar MD, WHO Fellowship in Diabetology. FICP, FCCP

ABSTRACT

Aims and objectives- To compare the platelet aggregation response in type 2 diabetes subjects and normal subjects. Research methods- 80 subjects with type 2 Diabetes Mellitus and 40 normal subjects were randomly selected. FPG, PPPG, HBA1c and platelet aggregation response were studied. Results - The mean age was 52.16±11.28 in the case group and 41.4±10.43 in the control group. There were 50 and 21 number of male subjects and 30 and 19 number of female subjects in the case and control group respectively. The mean fasting plasma glucose was 150.08±54.52 and 88.70±13.36 in the case and control group respectively. The mean post prandial plasma glucose was 233.98±82.99 and 129.95±15.27, mean HBA1c was 8.08±1.84 and 5.50±.42 in the case and control group respectively. The duration of diabetes ranged from newly detected diabetics to those with disease duration of more than 10 years. Platelet aggregation responses to ADP and epinephrine were measured and results were recorded as percentage for both groups. The difference between the case and control groups in the platelet aggregation responses induced was statistically insignificant. Conclusions- The platelet aggregation responses induced by ADP and epinephrine were similar in type 2 diabetes and normal subjects. So the routine use of anti platelet agents may not be necessary in all type 2 diabetes subjects for primary prevention of cardiovascular diseases. Anti platelet drugs can be used in secondary prevention and high risk patients. This is a small study done in a single centre. So a large multicentre study is necessary to prove this.